Treatment to prevent HIV transmission in serodiscordant couples in Henan, China, 2006 to 2012

Clinical Infectious Diseases

Volumn 61, Issue 1, 2015, Pages 111-119

  Smith, M Kumi ^a,b   Westreich, Daniel ^a   Liu, Huixin ^b   Zhu, Lin ^b   Wang, Lan ^c   He, Wensheng ^d   Zhou, Jianping ^d   Miller, William C ^e   Cohen, Myron S ^e   Wang, Ning ^b  

^a IL   (United States)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d Zhumadian Centre for Disease Control and Prevention   (China)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

China; HIV treatment as prevention; HIV AIDS; serodiscordant couples; sexual transmission

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHINA; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE CONTROL; DRUG EFFICACY; FEMALE; HAZARD RATIO; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SEROCONVERSION; SEXUAL TRANSMISSION; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VIRUS TRANSMISSION; DISEASE TRANSMISSION; FAMILY SIZE; HIV INFECTIONS; MIDDLE AGED; PREVENTION AND CONTROL; RISK ASSESSMENT; TRANSMISSION;

ADULT; ANTI-RETROVIRAL AGENTS; CHINA; COHORT STUDIES; DISEASE TRANSMISSION, INFECTIOUS; FAMILY CHARACTERISTICS; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK ASSESSMENT;

EID: 84953884171     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ200     Document Type: Article

References (37)

1. World Health Organization. Guidance on Couples HIV Testing and Counselling including Antiretroviral Therapy for Treatment and Prevention in Serodiscordant Couples Recommendations for a public health approach, 2010.
2. Panel on Antiretroviral Guidelines for Adolescents and Adults, Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents, 2013.
3. Hoen B, Bonnet F, Delaugerre C, et al. Review article French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults. J Int AIDS Soc 2014; 17: 1-15.
4. Cohen MS, Chen YQ, McCauleyM, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med 2011; 365: 493-505.
5. Kitahata MM, Gange S, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815-26.
6. Das M, Chu PL, Santos G-M, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010; 5: e11068.
7. Montaner JSG, Lima V, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376: 532-9.
8. Dukers N, Spaargaren J, Geskus R, Beijnen J, Coutinho R, Fennema H. HIV incidence on the increase among homosexual men attending an Amsterdam sexually transmitted disease clinic: using a novel approach for detecting recent infections. AIDS 2002; 16: F19-24.
9. Gupta R, Wainberg M, Brun-Vezinet F, et al. Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs. J Infect Dis 2013; 207: S101-6.
10. Crepaz N, Lyles C, Wolitski R, et al. Do prevention interventions reduce HIV risk behaviours among people living with HIV? A meta-analytic review of controlled trials. AIDS 2006; 20: 143-57.
11. Vitoria M, Vella S, Ford N. Scaling up antiretroviral therapy in resourcelimited settings: adapting guidance to meet the challenges. Curr Opin HIV AIDS 2013; 8: 12-8.
12. Muessig KE, Cohen MS. Advances in HIV prevention for serodiscordant couples. Curr HIV/AIDS Rep 2014; 11: 434-46.
13. He N, Duan S, Ding Y, et al. Antiretroviral therapy reduces HIV transmission in discordant couples in rural Yunnan, China. PLoS One 2013; 8: e77981.
14. Birungi J, Wang H, Ngolobe MH, et al. Lack of effectiveness of antiretroviral therapy (ART) as an HIV prevention tool for serodiscordant couples in a rural ART program without viral load monitoring in Uganda. In: 19th International AIDS Conference, 2012.
15. Wang L, Ge Z, Jing L, et al. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. J Acquir Immune Defic Syndr 2010; 55: 232-8.
16. Wang L, Wang L, Smith MK, et al. Heterosexual transmission of HIV and related risk factors among serodiscordant couples in Henan province, China. Chin Med J (Engl) 2013; 126: 3694-700.
17. Ma Y, Zhang F, Zhao Y, et al. Cohort profile: the Chinese national free antiretroviral treatment cohort. Int J Epidemiol 2010; 39: 973-9.
18. Granich R, Gilks C, Dye C, Cock K, Williams B. Universal voluntary HIV testing and immediate antiretroviral therapy-author's reply. Lancet 2009; 373: 48-57.
19. Wu Z, Rou K, Detels R. Prevalence of HIV infection among former commercial plasma donors in rural eastern China. Health Policy Plan 2001; 16: 41-6.
20. Wang L. Overview of the HIV/AIDS epidemic, scientific research and government responses in China. AIDS 2007; 21(Suppl 8): S3-7.
21. AIDS in China: anatomy of an epidemic. Economist 2005; 53-5.
22. Ray WA. Evaluating medication effects outside of clinical trials: newuser designs. Am J Epidemiol 2003; 158: 915-20.
23. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med 1991; 10: 585-98.
24. Robins JM. Association, causation, and marginal structural models. Synthese 1999; 121: 151-79.
25. Cole SR, Hernán M. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168: 656-64.
26. Hernán M, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 96: 440-8.
27. Westreich D, Cole SR, Tien PC, et al. Time scale and adjusted survival curves for marginal structural cox models. Am J Epidemiol 2010; 171: 691-700.
28. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999; 10: 37-48.
29. Liu H, Ma Y, Su Y, et al. Emerging Trends of HIV Drug Resistance in Chinese HIV-Infected Patients Receiving First-Line Highly Active Antiretroviral Therapy: A Systematic Review and Meta-Analysis. Clin Infect Dis 2014; 10: 1495-502.
30. Dou Z, Chen RY, Xu J, et al. Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002-09. Int J Epidemiol 2010; 39(Suppl 2): ii56-64.
31. Wang X, Wu Z. Factors associated with adherence to antiretroviral therapy among HIV/AIDS patients in rural China. AIDS 2007; 21: S149-55.
32. Hernán M. The hazards of hazard ratios. Epidemiology 2010; 21: 13-5.
33. Baggaley R, White R, Hollingsworth T, Boily M-C. Heterosexual HIV-1 infectiousness and antiretroviral use: systematic review of prospective studies of discordant couples. Epidemiology 2013; 24: 110-21.
34. Donnell D, Baeten J, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375: 2092-8.
35. Reynolds S, Makumbi F, Nakigozi G, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 2011; 25: 473-7.
36. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367: 399-410.
37. Jia Z, Mao Y, Zhang F, et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet 2013; 382: 1195-203.